<DOC>
	<DOCNO>NCT00888719</DOCNO>
	<brief_summary>Objective trial ass dose-dependency , efficacy safety estimate optimum dosage confirmatory study CWP-0403 50mg , 100mg give twice daily 12 week type 2 diabetes patient insufficiently control diet exercise comparison placebo .</brief_summary>
	<brief_title>Therapeutic Exploratory Study CWP-0403</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Age of≥25 &lt; 75 typeⅡ DM patient Patients whose level HbA1c 7.0 % le 10 % within 4weeks screen registration In spite dietary exercise treatment 8weeks , level HbA1c 6.5 % le 10 % . BMI 20kg/㎡ 40kg/㎡ Out patient patient agree trial participation write informed consent TypeⅠDM , Gestational diabetes . Patients treat insulin Fasting glucose level 250mg/dL Patients compliant dietary exercise treatment 8 week screen period . ( Evaluated `` Bad '' worse ) Severe hepatic dysfunction ( i.e . : uncompensated hepatic cirrhosis ) AST ALT level 2.5times high UNL screen visit . Severe renal dysfunction ( i.e . : renal failure ) serum creatinine level 1.5mg/dl Severe cardiac dysfunction ( i.e . : heart failure ) history myocardial infarction within 6months screen Chronic pulmonary disease pulmonary infarction Pancreatitis patient Patients treated life threaten disease cancer , severe trauma infection . Uncontrollable diabetic complication ( neuropathy , retinopathy , nephrosis ) Severe ketosis experience diabetic coma Intestinal disease affect digestion absorption history GI dissection surgery except appendectomy . Pregnant , expect pregnant nursing female Excessive alcohol consumption ( Over 80g alcohol/day : Over 1 bottle 360ml Soju/day ) Participants clinical trial within 3 month screen Patients medicate follow nonconcomitant medication Insulins oral antidiabetic Oral ( 1 week ) IV corticosteroid ( External inhale corticosteroid exclude ) appetite suppressant exenatide GLP1 analogues Other medication development Hypersensitive intolerance DPP4 inhibitory patient decide inappropriate trial subject investigator</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>